DNLI Stock Analysis: Buy, Sell, or Hold?
DNLI - Denali Therapeutics Inc. Common Stock
$26.48
0.80 (3.12%)
▲
5d:
+2.87%
30d:
+28.48%
90d:
+37.7%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 10, 2026
27d
Get Alerted When DNLI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called DNLI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DNLI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: DNLI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: DNLI is currently trading at $26.48, which is considered extended relative to its 30-day fair value range of $21.42 to $26.25.
Technical Outlook: Technically, DNLI is in a uptrend. Immediate support is located at $24.77, while resistance sits at $27.30. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $33.93 (+32.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DNLI is in a uptrend. Immediate support is located at $24.77, while resistance sits at $27.30. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $33.93 (+32.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$21.42 -
$26.25
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
56.3%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 32.1% below Wall St target ($33.93)
Trading Range Analysis
30-Day Trading Range
$21.42 -
$26.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$24.77
Resistance Level
$27.30
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.36
Wall Street Target
$33.93
(+32.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 13, 2026 4:21 PM ET
Data refreshes hourly during market hours. Next update: 5:21 PM
Data refreshes hourly during market hours. Next update: 5:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNLI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
